Krystal Biotech Inc (KRYS)

Krystal Biotech slips more than 2% even after Q4 earnings and revenue top estimatesFebruary 17, 2026 10:49 AM
IH Market News
Krystal Biotech Inc (NASDAQ:KRYS) on Tuesday delivered fourth-quarter results that came in ahead of Wall Street forecasts, though its shares moved lower in early trading.The stock declined 2.33% in pre-market activity despite the earnings beat.The gene therapy specialist reported adjusted earnings per share of $1.70, surpassing analyst expectations of $1.58 by $0.12. Quarterly revenue reached $107.1 million, modestly above the $106.16 million consensus and up 17.5% from $91.1 million in the same period a year earlier.Sales were driven entirely by VYJUVEK, the company’s therapy for dystrophic epidermolysis bullosa, which generated $107.1 million during the quarter.Krystal said it has obtained more than 660 reimbursement approvals for VYJUVEK across the United States and continues to report broad nationwide patient access.“In 2025, Krystal made meaningful progress on our mission to serve patients with dystrophic epidermolysis bullosa around the world, while continuing to build the global infrastructure required to scale our impact,” said Krish S. Krishnan, Chairman and CEO of Krystal Biotech.The company closed the quarter with $955.9 million in cash, cash equivalents, and investments as of December 31, 2025, underscoring a strong liquidity position. Gross margin remained high at 94% for the fourth quarter.Krystal also pointed to regulatory advances, including the FDA’s Regenerative Medicine Advanced Therapy designation for KB707 in advanced non-small cell lung cancer and Fast Track Designation for KB111 in Hailey-Hailey disease.Looking ahead to fiscal 2026, the company expects non-GAAP research and development as well as selling, general and administrative expenses to range between $175 million and $195 million.Krystal Biotech stock price

Original: Krystal Biotech slips more than 2% even after Q4 earnings and revenue top estimates

KRYS. Under $200

KRYS new 52 week high

KRYS 10Q due 5/6

KRYS over $30

KRYS new 52 week high

From Cathie Wood
A Novel Gene Therapy Promises Relief For A Rare Genetic Skin Disorder
ARK Invest_Illustration_Pierce Jamieson_Final_Circle 400 px By Pierce Jamieson | @PierceARK
Research Associate
Recently, the US Food and Drug Administration (FDA) approved Krysta Biotech’s (KRYS) groundbreaking advance1 in gene therapy, Vyjuvek, to treat wounds in patients suffering from dystrophic epidermolysis bullosa (DEB), a rare and serious genetic skin disorder caused by mutations in the collagen Type VII alpha 1 chain (COL7A1) gene. As the first FDA-approved gene therapy for DEB, Vyjuvek is a significant breakthrough.

Vyjuvek uses a genetically modified HSV-1 to deliver normal copies of the COL7A1 gene to wounds, restoring the integrity of the skin with fibrils that hold skin layers together. Treated with Vyjuvek, 65% of wounds closed completely.

Moving nicely today...

Looking at the few posts here there seems to be no real commitment here...any thoughts on KRYS? Hype or something brewing?

In the last 3 months, 5 ranked analysts set 12-month price targets for KRYS. The average price target among the analysts is $125.00. Analysts compare their price target to the current market price of the stock to determine how much potential upside or downside movement there could be in the stock price. High $140 Low $111

30 Nov Tues releases this PR during evening after market close:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-pricing-200-million-public-offering

29 Nov Mon after market closes release this PR:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-proposed-200-million-public-offering

29 Nov Monday pre-market news release, great move pre-market approx 7am and so far holding fairly well:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-positive-topline-results-gem-3-pivotal

This caught my eye on Monday, the huge move off the PR...I'm guessing here saw the same. Any real thoughts regarding the company and this PR. I have not gotten a chance to dig into it. Hoping to have somm DD done over the weekend.

Holding well so far, why the pretty hard drop?

Why are you surprised? Serious question, not being impudent...

200 million dollar offering. Won't be surprised to see it drop pretty hard when the market opens

Surprised it held up this long

Large tutes holdings. Some taking huge gains before years end.

Not sure this kind of gain is sustainable. May see a big pullback

3rd post

Krystal Biotech shares are trading higher after the company announced its GEM-3 trial met its primary endpoint.

..